At the time of writing, Humacyte Inc [HUMA] stock is trading at $4.64, up 34.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The HUMA shares have gain 13.17% over the last week, with a monthly amount glided 5.22%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Humacyte Inc [NASDAQ: HUMA] stock has seen the most recent analyst activity on December 20, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $15 from $12. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 11, 2023, and set its price target to $6. On August 14, 2023, upgrade upgraded it’s rating to Neutral and revised its price target to $3.50 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $6 on June 22, 2023. Piper Sandler downgraded its rating to a Underweight and reduced its price target to $4 on May 16, 2022. Cowen started tracking with a Outperform rating for this stock on October 29, 2021, and assigned it a price target of $17. In a note dated September 24, 2021, Oppenheimer initiated an Outperform rating and provided a target price of $16 on this stock.
For the past year, the stock price of Humacyte Inc fluctuated between $2.48 and $9.97. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Humacyte Inc [NASDAQ: HUMA] shares were valued at $4.64 at the most recent close of the market. An investor can expect a potential return of 72.41% based on the average HUMA price forecast.
Analyzing the HUMA fundamentals
Gross Profit Margin for this corporation currently stands at 0.35% with Operating Profit Margin at -10.43%, Pretax Profit Margin comes in at -14.17%, and Net Profit Margin reading is -14.17%. To continue investigating profitability, this company’s Return on Assets is posted at -1.33, Equity is 11.69 and Total Capital is -1.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.80 points at the first support level, and at 2.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.12, and for the 2nd resistance point, it is at 7.61.
Ratios To Look Out For
It is important to note that Humacyte Inc [NASDAQ:HUMA] has a current ratio of 1.10. On the other hand, the Quick Ratio is 1.10, and the Cash Ratio is 0.98.
Transactions by insiders
Recent insider trading involved Constantino Michael T., Director, that happened on Dec 04 ’24 when 4600.0 shares were purchased. President, CEO and Director, Niklason Laura E completed a deal on Nov 19 ’24 to buy 1797.0 shares. Meanwhile, Director Dougan Brady W bought 1797.0 shares on Nov 19 ’24.
